PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
35.97%
Some net income increase while CRVO is negative at -30.28%. John Neff would see a short-term edge over the struggling competitor.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Deferred tax of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
-6.03%
Negative yoy SBC while CRVO is 0.00%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-150.99%
Both reduce yoy usage, with CRVO at -500.65%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-123.01%
Both negative yoy AP, with CRVO at -88.59%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-179.37%
Both reduce yoy usage, with CRVO at -281.71%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-42.60%
Negative yoy while CRVO is 111.77%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-14.43%
Both yoy CFO lines are negative, with CRVO at -56.33%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.